Clinical trial · Observational
Role of Axumin PET Scan in Germ Cell Tumor
Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic Acid (Axumin) Positron Emission Tomography/Computed Tomography Prior to Retroperitoneal Lymph Node Dissection for Testicular Cancer
NCT03426865CI-TRIAL-00093428TESTPETcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.
Conditions
Conditions (13)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Germ Cell Cancer Metastatic | — | UNRESOLVED | — |
| Germ Cell Cancer, Nos | Malignant Germ Cell Tumor | ALIAS | 0.90 |
| Germ Cell Neoplasm of Retroperitoneum | Retroperitoneal Germ Cell Tumor | ALIAS | 0.90 |
| Germ Cell Tumor | Germ Cell Tumor | ONTOLOGY_EXACT | 0.90 |
| Germ Cell Tumor of Testis | Testicular Germ Cell Tumor | ALIAS | 0.90 |
| Germ Cell Tumor, Testicular, Childhood | Testicular Germ Cell Tumor | ONTOLOGY_EXACT | 0.85 |
| Testicular Cancer | Malignant Testicular Neoplasm | CURATED_EXACT | 0.92 |
| Testicular Choriocarcinoma | Testicular Choriocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Testicular Diseases | — | UNRESOLVED |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Axumin PET scan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Axumin PET scan
- description
- Only one arm is being evaluated--the arm receiving PET scan
- interventionNames
- Drug: Axumin PET scan
Primary outcomes (1)
- measure
- Performance characteristics of Axumin PET scan in patients undergoing retroperitoneal lymph node dissection
- timeFrame
- Two years
- description
- Investigate the accuracy of anti-18F-FACBC PET/CT correlating with histopathologic outcomes
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed NSGCT after orchiectomy who are scheduled to undergo primary RPLND or post-chemotherapy RPLND * Patients must be over 18 years old and capable and willing to provide informed consent. * Medically stable as judged by patient's physician. * Life expectancy must be estimated at \> 6 months. * Patients must have an ECOG performance status of 0-3 (restricted to ECOG PS 0-2 if age \>70 years). * Patient must be able to lie still for a 20 to 30 minute PET/CT scan. Patients will be asked if they have problems or issues with lying flat Exclusion Criteria: * Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to anti-18F-FACBC are NOT eligible. * Patients with liver failure are NOT eligible. * Patients currently undergoing chemotherapy or chemotherapy within two weeks of anti-18F-FACBC PET/CT scan are NOT eligible
References
Publications (0)
Data not yet available
No reference posted for this study.